Results 261 to 270 of about 102,788 (290)
Some of the next articles are maybe not open access.
Cutaneous manifestations of B-cell chronic lymphocytic leukemia
International Journal of Hematology, 2020Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative disease characterized by the accumulation of immature monoclonal B lymphocytes in blood cells, bone marrow, spleen and lymph nodes. This is the most common type of leukemia among the Caucasoid race.
Elena A. Morozova +2 more
openaire +3 more sources
T-lymphocyte function in B-cell chronic lymphocytic leukemia
Clinical Immunology and Immunopathology, 1980Summary. B‐enriched lymphocyte populations from patients with chronic lymphocytic leukaemia (CLL) were compared to B‐enriched lymphocyte populations from normal age‐matched controls for their ability to stimulate a proliferative response and to generate cytotoxic cells in allogeneic mixed lymphocyte cultures (MLC).
Frederick R. Davey, Jeffrey A. Wolos
openaire +5 more sources
B cell chronic lymphocytic leukemia with meningeal infiltration by T lymphocytes
European Journal of Internal Medicine, 2003Chronic lymphocytic leukemia (CLL) is a generalized malignancy of the lymphoid tissue characterized by an accumulation of monoclonal lymphocytes, usually of the B cell type. Involvement of the central nervous system is a rare complication, usually seen in T cell leukemias.
Tatiana Bezayová +2 more
openaire +3 more sources
The normal counterpart to the chronic lymphocytic leukemia B cell
Best Practice & Research Clinical Haematology, 2007Chronic lymphocytic leukemia (CLL) is characterized by the monoclonal expansion of small mature-looking B cells that accumulate in the blood, marrow, and lymphoid organs, and have a remarkable phenotypic homogeneity. By definition, CLL cells co-express CD5 and CD23 with faint to undetectable amounts of monoclonal surface immunoglobulins (sIg).
Caligaris Cappio F +1 more
openaire +3 more sources
Alemtuzumab for B-cell chronic lymphocytic leukemia
Expert Review of Anticancer Therapy, 2008Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleoside analogs.
openaire +3 more sources
Multidrug Resistance in B-Cell Chronic Lymphocytic Leukemia
Acta Haematologica, 1995Multidrug resistance (MDR) was investigated in peripheral blood cells isolated from 40 patients with B cell chronic lymphocytic leukemia (B-CLL) and from 7 healthy volunteers, using a flow cytometric assay that detects cellular efflux of the fluorescent dye rhodamine 123 (Rh 123), which has been demonstrated to be transported from the cell by the P ...
P.-Y. le Prise +5 more
openaire +3 more sources
Trisomy 8 in B-cell chronic lymphocytic leukemia
Cancer Genetics and Cytogenetics, 2008Association between trisomy 8 and myeloid disorders/malignancies has been well documented. We report on two patients with a known history of B-cell chronic lymphocytic leukemia (B-CLL) with bone marrow involvement. In addition to the classic B-CLL cytogenetic abnormalities in one of the patients, both showed a trisomy 8 clone in their bone marrow ...
Olga Pozdnyakova +4 more
openaire +3 more sources
Targeting B Cell Signaling in Chronic Lymphocytic Leukemia
Current Oncology Reports, 2017In recent years, a revolution in the management of chronic lymphocytic leukemia (CLL) has centered on the targeting of the B cell receptor (BCR) signaling pathway. Our improved understanding of the biology of cell signaling in CLL and the development of oral kinase inhibitors directed at the BCR pathway has led to the approval of two new agents and has
Jennifer R. Brown, Jon E. Arnason
openaire +3 more sources
The neurologic complications of B-cell chronic lymphocytic leukemia [PDF]
Neurology, 1997 We performed a retrospective study to characterize the type, frequency, and timing of neurologic complications in patients with B-cell chronic lymphocytic leukemia (B-CLL). We reviewed 962 total charts with a median follow-up time of 57.5 months. There were 109 cases (11.3%) of neurologic complications, including 69 cases (7.2%) of herpes zoster ...
James H. Bower +3 more
openaire +2 more sources
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2008A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over 5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL). The goal of this study was to investigate the relation between MBL and CLL.We investigated 1520 subjects who were 62 to 80 ...
Andy C. Rawstron +10 more
openaire +3 more sources